All India Institute of Medical Sciences.
J Appl Clin Med Phys. 2014 Mar 6;15(2):4670. doi: 10.1120/jacmp.v15i2.4670.
This study compares the dosimetry of high-dose-rate intracavitary brachytherapy (HDR-ICBT) performed with and without general anesthesia/spinal anesthesia (GA/SA) in patients with cervical carcinoma. We retrospectively retrieved the records of 138 HDR-ICBT applicator insertions performed in 46 patients: 69 performed with GA/SA (anesthesia group known as AG) in 23 patients, and 69 performed without GA/SA (nonanesthesia group known as NAG) in 23 patients. The intracavitary brachytherapy (ICBT) application was done with central tandem and two vaginal ovoids. For each ICBT plan, a high-dose-rate (HDR) dose of 7 Gy was prescribed to point A. From each plan, the doses to Point B right (B(R)), Point B left (B(L)), bladder and rectal reference points (Bladder(ref) and Rectal(ref)) were recorded and compared in the two groups. Student's t-test was applied to find out the significance of difference. The two groups were comparable in terms of demography and clinical characteristics. Mean Point BL doses in AG and NAG were 1.89 Gy (27% of Point A dose) and 1.82 Gy (26% of Point A dose), respectively. Mean Point BR doses in AG and NAG were 1.91 Gy (27% of Point A dose) and 1.85 Gy (26% of point A), respectively (p-value 0.7). The mean dose to Bladder(ref) in AG and NAG was 5.03 Gy and 4.90 Gy, respectively (p-value 0.6). The mean dose to Rectal(ref) was significantly higher in AG than NAG (5.09 Gy vs. 4.49 Gy, p-value 0.01). Although based on conventional 2D dosimetry planning, our study has demonstrated that avoiding GA/SA does not result in inferior HDR-ICBT dosimetry.
本研究比较了宫颈癌患者行高剂量率腔内近距离放疗(HDR-ICBT)时使用全身麻醉/椎管内麻醉(GA/SA)与不使用 GA/SA(非麻醉组,NAG)的剂量学差异。我们回顾性分析了 46 例患者的 138 次 HDR-ICBT 施源器插入术,其中 23 例患者接受 GA/SA(麻醉组,AG),23 例患者未接受 GA/SA(非麻醉组,NAG)。腔内近距离放疗(ICBT)应用中央串联和两个阴道后装施源器。每个 ICBT 计划中,A 点处方剂量为 7Gy 的高剂量率(HDR)。从每个计划中,记录并比较两组中 B 点右(B(R))、B 点左(B(L))、膀胱和直肠参考点(Bladder(ref) 和 Rectal(ref))的剂量。采用 Student's t 检验比较两组之间的差异。两组在人口统计学和临床特征方面具有可比性。AG 组和 NAG 组的平均 B 点左剂量分别为 1.89Gy(A 点剂量的 27%)和 1.82Gy(A 点剂量的 26%)。AG 组和 NAG 组的平均 B 点右剂量分别为 1.91Gy(A 点剂量的 27%)和 1.85Gy(A 点剂量的 26%)(p 值 0.7)。AG 组和 NAG 组的平均膀胱参考点剂量分别为 5.03Gy 和 4.90Gy(p 值 0.6)。AG 组直肠参考点剂量明显高于 NAG 组(5.09Gy 比 4.49Gy,p 值 0.01)。尽管本研究基于传统的二维剂量学计划,但结果表明避免 GA/SA 并不导致 HDR-ICBT 剂量学效果降低。